| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Wudarsky, R Nicolson, S D Hamburger, L Spechler, P Gochman, J Bedwell, M C Lenane, J L Rapopor. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. Journal of child and adolescent psychopharmacology. vol 9. issue 4. 2000-01-28. PMID:10630453. |
the national institute of mental health patients--13 females, 22 males (mean age, 14.1+/-2.3 years; range, 9.1-19 years) with childhood onset schizophrenia (n = 32), or psychotic disorder not otherwise specified (nos) (n = 3) with onset of psychosis before age 13--were recruited for open or double-blind trials of haloperidol, clozapine, or olanzapine. |
2000-01-28 |
2023-08-12 |
Not clear |
| C R Ashby, R Y Wan. Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse (New York, N.Y.). vol 24. issue 4. 2000-01-27. PMID:10638826. |
subsequently, clinical studies have shown that clozapine is effective in ameliorating the core symptoms, as well as the negative symptoms, in schizophrenia. |
2000-01-27 |
2023-08-12 |
Not clear |
| S M Dursun, A Szemis, H Andrews, M A Revele. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. Journal of psychiatry & neuroscience : JPN. vol 24. issue 5. 2000-01-20. PMID:10586536. |
the effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. |
2000-01-20 |
2023-08-12 |
Not clear |
| S M Dursun, A Szemis, H Andrews, M A Revele. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. Journal of psychiatry & neuroscience : JPN. vol 24. issue 5. 2000-01-20. PMID:10586536. |
to investigate the effects of 12 weeks of clozapine treatment on levels of cholesterol and related lipids in patients with schizophrenia. |
2000-01-20 |
2023-08-12 |
Not clear |
| J G Burke, S M Dursun, M A Revele. Refractory symptomatic schizophrenia resulting from frontal lobe lesion: response to clozapine. Journal of psychiatry & neuroscience : JPN. vol 24. issue 5. 2000-01-20. PMID:10586537. |
refractory symptomatic schizophrenia resulting from frontal lobe lesion: response to clozapine. |
2000-01-20 |
2023-08-12 |
Not clear |
| A Szegedi, I Anghelescu, J Wiesner, S Schlegel, H Weigmann, S Härtter, C Hiemke, H Wetze. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry. vol 32. issue 4. 2000-01-19. PMID:10505485. |
addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. |
2000-01-19 |
2023-08-12 |
Not clear |
| E Stip, I Lussier, P Lalonde, A Luyet, J Fabia. [Atypical neuroleptics and selective attention]. L'Encephale. vol 25. issue 3. 1999-12-29. PMID:10434152. |
the aim of this study was to examine selective attention in patients with chronic and refractory schizophrenia who had been exposed for six months to atypical neuroleptic medications: risperidone or clozapine. |
1999-12-29 |
2023-08-12 |
Not clear |
| R E See, A A Fido, M Maurice, M M Ibrahim, G M Salam. Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia. Biological psychiatry. vol 45. issue 12. 1999-12-20. PMID:10376128. |
previous studies have shown an increase in plasma levels of norepinephrine (ne) after clozapine treatment of schizophrenia. |
1999-12-20 |
2023-08-12 |
Not clear |
| J P McEvoy, O Freudenreich, W H Wilso. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biological psychiatry. vol 46. issue 1. 1999-12-20. PMID:10394482. |
smoking and therapeutic response to clozapine in patients with schizophrenia. |
1999-12-20 |
2023-08-12 |
Not clear |
| E Skogh, F Bengtsson, C Nordi. Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. Therapeutic drug monitoring. vol 21. issue 5. 1999-12-14. PMID:10519459. |
a 35-year-old man with schizophrenia was successfully treated with clozapine at a daily oral dose of 700-725 mg for more than 7 consecutive years. |
1999-12-14 |
2023-08-12 |
Not clear |
| T C Manschreck, D A Redmond, S F Candela, B A Mahe. Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. The Journal of neuropsychiatry and clinical neurosciences. vol 11. issue 4. 1999-12-13. PMID:10570762. |
effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. |
1999-12-13 |
2023-08-12 |
Not clear |
| T C Manschreck, D A Redmond, S F Candela, B A Mahe. Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. The Journal of neuropsychiatry and clinical neurosciences. vol 11. issue 4. 1999-12-13. PMID:10570762. |
this study focused on the symptomatic and cognitive effects of the atypical antipsychotic clozapine in chronic hospitalized schizophrenia patients. |
1999-12-13 |
2023-08-12 |
Not clear |
| G E Duncan, S Zorn, J A Lieberma. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Molecular psychiatry. vol 4. issue 5. 1999-12-10. PMID:10523814. |
available evidence indicates that clozapine is the most effective antipsychotic currently used for the pharmacotherapy of schizophrenia. |
1999-12-10 |
2023-08-12 |
Not clear |
| G E Duncan, S Zorn, J A Lieberma. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Molecular psychiatry. vol 4. issue 5. 1999-12-10. PMID:10523814. |
the present paper briefly reviews the clinical experience with the newer 'atypical' antipsychotic drugs and then discusses clinical and preclinical data potentially relevant to mechanisms of action of clozapine in relation to the nmda receptor hypofunction hypothesis of schizophrenia. |
1999-12-10 |
2023-08-12 |
Not clear |
| K I Melkersson, A L Hulting, K E Brisma. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. The Journal of clinical psychiatry. vol 60. issue 11. 1999-12-08. PMID:10584769. |
different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. |
1999-12-08 |
2023-08-12 |
Not clear |
| G M Simpson, R C Josiassen, J K Stanilla, J de Leon, C Nair, G Abraham, A Odom-White, R M Turne. Double-blind study of clozapine dose response in chronic schizophrenia. The American journal of psychiatry. vol 156. issue 11. 1999-11-16. PMID:10553738. |
double-blind study of clozapine dose response in chronic schizophrenia. |
1999-11-16 |
2023-08-12 |
Not clear |
| G E Tsai, P Yang, L C Chung, I C Tsai, C W Tsai, J T Coyl. D-serine added to clozapine for the treatment of schizophrenia. The American journal of psychiatry. vol 156. issue 11. 1999-11-16. PMID:10553752. |
d-serine added to clozapine for the treatment of schizophrenia. |
1999-11-16 |
2023-08-12 |
Not clear |
| S M Dursun, D McIntosh, H Millike. Clozapine plus lamotrigine in treatment-resistant schizophrenia. Archives of general psychiatry. vol 56. issue 10. 1999-10-29. PMID:10530638. |
clozapine plus lamotrigine in treatment-resistant schizophrenia. |
1999-10-29 |
2023-08-12 |
Not clear |
| S Pallanti, L Quercioli, A Pazzagl. Effects of clozapine on awareness of illness and cognition in schizophrenia. Psychiatry research. vol 86. issue 3. 1999-10-21. PMID:10482343. |
effects of clozapine on awareness of illness and cognition in schizophrenia. |
1999-10-21 |
2023-08-12 |
Not clear |
| P Hertel, M V Fagerquist, T H Svensso. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science (New York, N.Y.). vol 286. issue 5437. 1999-10-21. PMID:10506554. |
these results challenge basic assumptions underlying the dopamine hypothesis of schizophrenia and provide insight into clozapine's mode of action. |
1999-10-21 |
2023-08-12 |
rat |